Join the 'Januvia' group to help and get support from people like you. How it works

Januvia Blog

Blog (6)

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

Posted 9 Apr 2012 by Drugs.com

Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin] injection) to include data showing superior blood sugar control when compared to Januvia (sitagliptin). Victoza also provided greater weight reduction. Both products were taken in combination with metformin in adults with type 2 diabetes. The update also includes data demonstrating the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes. “We’re pleased to expand the Victoza product label to include data demonstrating superior efficacy over Januvia, said Camille Lee, Corporate Vice President, Diabetes Marketing at Novo Nordisk. “The additional data supporting combination therapy with basal insulin further demonstrates that Victoza is ... Read more

Related support groups: Diabetes, Type 2, Victoza, Januvia, Liraglutide, Sitagliptin

Prescription Meds Can Put on Unwanted Pounds

Posted 2 Mar 2012 by Drugs.com

FRIDAY, March 2 – Medications taken by millions of Americans for mood disorders, high blood pressure, diabetes and other chronic conditions can have an unhealthy side effect: weight gain. While other choices exist for some types of drugs, adjusting medications is not simply a matter of switching, said Ryan Roux, chief pharmacy officer with the Harris County Hospital District, in Houston. In the late 1990s, Dr. Lawrence Cheskin conducted early research on prescription medicines and obesity. "Some medicines make an early, noticeable difference, causing patients to become ravenously hungry, while changes are subtle for others. A few months taking them and you've gained 10 pounds," said Cheskin, now director of the Johns Hopkins Weight Management Center, in Baltimore. To help increase awareness, Roux and his pharmacist group have compiled a list of "weight-promoting" and "weight-neutral or ... Read more

Four Common Meds Send Thousands of Seniors to Hospital: CDC

Posted 23 Nov 2011 by Drugs.com

WEDNESDAY, Nov. 23 – An estimated 100,000 older Americans are hospitalized for adverse drug reactions yearly, and most of those emergencies stem from four common medications, a new study finds. The four types of medication – two for diabetes and two blood-thinning agents – account for two-thirds of those drug-related emergency hospitalizations. "Of the thousands of medications available to older patients, a small group of blood thinners and diabetes medications caused a high proportion of emergency hospitalizations for adverse drug events among elderly Americans," said lead study author Dr. Daniel Budnitz, director of the U.S. Centers for Disease Control and Prevention's medication safety program. Medications previously designated "high-risk" were implicated in only 1.2 percent of hospitalizations, the study found. Working with a nationally representative database, CDC researchers ... Read more

Related support groups: Metformin, Aspirin, Coumadin, Plavix, Warfarin, Insulin, Lantus, Januvia, Glucophage, Actos, Glyburide, Glipizide, Humalog, Janumet, Novolog

FDA Approves Combination Therapy Juvisync

Posted 7 Oct 2011 by Drugs.com

SILVER SPRING, Md., Oct. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin. About 20 million people in the United States have type 2 diabetes, and they often have high cholesterol levels as well. These conditions can lead to increased risk of heart disease, stroke, kidney disease and blindness, among other chronic conditions, particularly if left untreated or poorly treated. Sitagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that enhances the body's own ability to lower elevated blood sugar and is approved for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. Simvastatin is an ... Read more

Related support groups: Diabetes, Type 2, High Cholesterol, Simvastatin, Januvia, Zocor, Sitagliptin

Popular Diabetes Drugs May Raise Pancreatic Cancer Risk, Study Suggests

Posted 22 Sep 2011 by Drugs.com

THURSDAY, Sept. 22 – People with type 2 diabetes taking the drugs Januvia or Byetta might have an increased risk of developing pancreatitis and pancreatic cancer, a preliminary study suggests. The study also found that Byetta (exenatide) may raise the risk of thyroid cancer. Although the links aren't conclusive, they merit further investigation, the researchers noted. "We have raised concern that there may be a link, but we haven't confirmed it," said lead researcher Dr. Peter Butler, director of the Larry L. Hillblom Islet Research Center at the University of California, Los Angeles. "We need to do more work to figure out whether this is real or not." Both drugs help control blood sugar levels by encouraging production of a hormone called glucagon-like peptide 1 (GLP-1). Januvia (sitagliptin) and Byetta, an injectable drug, are a new way of treating type 2 diabetes, and they ... Read more

Related support groups: Diabetes, Type 2, Januvia, Byetta, Pancreatitis, Pancreatic Cancer

FDA Approves Redesigned Labels for Some Merck Drugs

Posted 13 Jun 2011 by Drugs.com

Changes developed under Merck's Label Standardization Project SILVER SPRING, Md., June 10, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today is announcing the approval of Merck's redesigned drug container labels that include a new standardized format to improve readability and provide better information on product and strength differentiation. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Merck's Label Standardization Project includes the revision of 34 container labels for 16 solid oral drug products regulated by the FDA's Center for Drug Evaluation and Research (CDER). Drugs affected by the revisions include: Cozaar, Crixivan, Hyzaar, Isentress, Janumet, Januvia, Mevacor, Noroxin, Prinivil, Prinzide, Propecia, Proscar, Singulair, Zocor, and Zolinza. "We commend Merck for their efforts," said Janet Woodcock, M.D., director of CDER. "This was n ... Read more

Related support groups: Singulair, Januvia, Cozaar, Zocor, Hyzaar, Janumet, Propecia, Proscar, Prinzide, Noroxin, Prinivil, Mevacor, Isentress, Crixivan, Zolinza

Injection Helps Treat Hard-to-Control Type 2 Diabetes

Posted 23 Apr 2010 by Drugs.com

FRIDAY, April 23 – Patients with type 2 diabetes who can't control their blood glucose levels with the drug metformin alone do better after adding injections of the drug liraglutide compared to oral doses of another drug called sitagliptin, researchers report. In the study, Dr. Richard E. Pratley, of the University of Vermont College of Medicine in Burlington, and his colleagues randomly assigned patients whose blood glucose wasn't sufficiently controlled by metformin (Glucophage) to receive 26 weeks of treatment with liraglutide (Victoza) by injection or sitagliptin (Januvia) by mouth. The researchers found that the patients did better on liraglutide, although between 21 percent and 27 percent of patients reported nausea, compared to 5 percent of those on sitagliptin, according to the report published in the April 24 issue of The Lancet. Liraglutide "was well-tolerated with minimum ... Read more